- $17.33bn
- $17.77bn
- $2.07bn
- 97
- 11
- 94
- 76
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 54.79 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -15.27% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.3 | ||
| Price to Tang. Book | 16.33 | ||
| Price to Free Cashflow | 58.49 | ||
| Price to Sales | 8.37 | ||
| EV to EBITDA | 45.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.07% | ||
| Return on Equity | 43.03% | ||
| Operating Margin | 14.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 904.4 | 1,098.8 | 1,305.3 | 1,697.1 | 2,071.6 | 2,448.44 | 2,874.91 | 22.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -65.39 | +628.98 | -65.7 | +1041.48 | +96.55 | -27.13 | +22.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Directors
- Timothy Scannell NEC
- Shacey Petrovic PRE (47)
- Wayde McMillan CFO (51)
- Charles Alpuche COO (61)
- Dan Manea CHO (54)
- Bret Christensen EVP (50)
- John Kapples SVP (61)
- Eric Benjamin SVP (38)
- Michael Spears SVP (56)
- Luciana Borio DRC
- Elizabeth Weatherman DRC (61)
- Wayne Frederick IND (49)
- James Hollingshead IND (58)
- Jessica Hopfield IND (56)
- David Lemoine IND (73)
- Michael Minogue IND (54)
- Corinne Nevinny IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 20th, 2000
- Public Since
- May 15th, 2007
- No. of Shareholders
- 6
- No. of Employees
- 3,900
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 70,226,104
- Address
- 100 Nagog Park, ACTON, 01720-3440
- Web
- https://www.omnipod.com
- Phone
- +1 9786007000
- Contact
- Deborah Gordon
- Auditors
- Grant Thornton LLP
Latest News for PODD
Upcoming Events for PODD
Q1 2025 Insulet Corp Earnings Release
Q1 2025 Insulet Corp Earnings Call
Insulet Corp Annual Shareholders Meeting
Insulet Corp- Investor Day 2025
Q2 2025 Insulet Corp Earnings Release
Similar to PODD
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 21:19 UTC, shares in Insulet are trading at $246.80. This share price information is delayed by 15 minutes.
Shares in Insulet last closed at $246.80 and the price had moved by +48.44% over the past 365 days. In terms of relative price strength the Insulet share price has outperformed the S&P500 Index by +39.58% over the past year.
The overall consensus recommendation for Insulet is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreInsulet does not currently pay a dividend.
Insulet does not currently pay a dividend.
Insulet does not currently pay a dividend.
To buy shares in Insulet you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $246.80, shares in Insulet had a market capitalisation of $17.33bn.
Here are the trading details for Insulet:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PODD
Based on an overall assessment of its quality, value and momentum Insulet is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Insulet is $315.96. That is 28.02% above the last closing price of $246.80.
Analysts covering Insulet currently have a consensus Earnings Per Share (EPS) forecast of $4.22 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Insulet. Over the past six months, its share price has outperformed the S&P500 Index by +15.6%.
As of the last closing price of $246.80, shares in Insulet were trading +1.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Insulet PE ratio based on its reported earnings over the past 12 months is 54.79. The shares last closed at $246.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Insulet's management team is headed by:
- Timothy Scannell - NEC
- Shacey Petrovic - PRE
- Wayde McMillan - CFO
- Charles Alpuche - COO
- Dan Manea - CHO
- Bret Christensen - EVP
- John Kapples - SVP
- Eric Benjamin - SVP
- Michael Spears - SVP
- Luciana Borio - DRC
- Elizabeth Weatherman - DRC
- Wayne Frederick - IND
- James Hollingshead - IND
- Jessica Hopfield - IND
- David Lemoine - IND
- Michael Minogue - IND
- Corinne Nevinny - IND